Real World Overall Survival of Patients With Metastatic Renal Cell Carcinoma Treated With Only Available Sunitinib and Pazopanib in First-Line Setting

BACKGROUND: The emerging new standard of care for metastatic clear cell renal carcinoma (mRCC) becomes a challenge when access to new drugs is limited. In Serbia, sunitinib and pazopanib are the only available first-line therapies. The second-line treatment for mRCC has never been and is still not a...

Descripción completa

Detalles Bibliográficos
Autores principales: Nikic, Predrag, Babovic, Nada, Dzamic, Zoran, Salma, Svetlana, Stojanovic, Vesna, Matkovic, Suzana, Pejcic, Zoran, Juskic, Kristina, Soldatovic, Ivan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9213683/
https://www.ncbi.nlm.nih.gov/pubmed/35756652
http://dx.doi.org/10.3389/fonc.2022.892156

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9213683/
https://www.ncbi.nlm.nih.gov/pubmed/35756652
http://dx.doi.org/10.3389/fonc.2022.892156

Ejemplares similares